Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Von Hoff

Medical Oncology Scottsdale, AZ Medical Doctor

NPI 1194700724 CMS profile 8802

13400 E Shea Blvd, Scottsdale, AZ 85259

Open in the dashboard

General payments

$165,351

53 records reported · program years 2019–2025

Research payments

$7,743

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,356,368 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Daniel Von Hoff of Scottsdale, AZ is reported in the CMS Open Payments database as having received $165,351 across 53 general payments and $7,743 in research payments paid to them. Separately, studies naming them as principal investigator received $2,356,368 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,633 8
2024 General $61,022 13
2023 General $25,827 4
2022 General $10,759 4
2022 Research $1,125 1
2021 General $2,880 2
2020 General $9,375 6
2019 General $21,856 16
2019 Research $6,618 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Von Hoff
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Daniel Von Hoff were reported at $33,633. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Daniel Von Hoff Medical Oncology median Middle half National median
2019 $21,856 $968 $140–$6,658 $163
2020 $9,375 $747 $102–$5,891 $114
2021 $2,880 $430 $50–$4,098 $132
2022 $10,759 $812 $127–$4,907 $149
2023 $25,827 $957 $144–$5,248 $160
2024 $61,022 $1,042 $149–$5,650 $164
2025 $33,633 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $53,705 15 payments
  2. Sumitomo Pharma America, Inc. $53,095 15 payments
  3. BioXcel Therapeutics, Inc. $24,000 2 payments
  4. EMD Serono, Inc. $23,169 11 payments
  5. E.R. Squibb & Sons, L.L.C. $3,900 1 payment
  6. Swedish Orphan Biovitrum AB $3,900 2 payments
  7. Corcept Therapeutics $2,000 4 payments
  8. Seattle Genetics, Inc. $1,380 1 payment
  9. Progenics Pharmaceuticals, Inc. $109 1 payment
  10. Boston Scientific Corporation $94 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $159,624 35 payments
  2. Travel and Lodging $4,634 7 payments
  3. Food and Beverage $1,094 11 payments
Products named General payments · program years 2019–2025
  1. RETHYMIC $25,500 5 payments
  2. IGALMI $24,000 2 payments
  3. KINERET $3,900 2 payments
  4. Korlym $2,000 4 payments
  5. PYLARIFY $109 1 payment
  6. HABIB ENDOHPB $94 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Celgene Corporation $6,618 1 payment
  2. Onquality Pharmaceuticals USA LLC $1,125 1 payment

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record